Melanin as a potential target for radionuclide therapy of metastatic melanoma

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Melanoma is diagnosed in approximately 100,000 patients worldwide and for those with metastatic disease, the 5-year survival is extremely poor at just 6%, because there are no satisfactory treatments. Targeted radionuclide therapy is currently gaining momentum and has evolved into an efficient modality for the treatment of patients with malignancies such as non-Hodgkins lymphoma in whom standard antineoplastic therapies are not effective. Melanoma is named after the pigment melanin, which in turn is derived from the Greek word for black. Most melanomas are pigmented by the presence of melanin, some of which is extracellular as a result of cellular turnover. Thus, melanin presents a promising target for the drugs carrying a cytotoxic payload of radiation provided such therapies spare other melanotic tissues. There are a variety of substances that could potentially serve as delivery vehicles of radionuclides for the treatment of melanoma. These substances can be divided into melanin binders, melanin precursors and binders to melanogenesis-related proteins. The authors are optimistic that therapeutic agents targeting melanin to deliver radionuclide therapy could appear in the clinic within a decade.

Original languageEnglish (US)
Pages (from-to)541-549
Number of pages9
JournalFuture Oncology
Volume1
Issue number4
DOIs
StatePublished - Aug 2005

Fingerprint

Melanins
Radioisotopes
Melanoma
Therapeutics
Antineoplastic Agents
Non-Hodgkin's Lymphoma
Radiation
Survival
Pharmaceutical Preparations

Keywords

  • compounds binding to melanin
  • compounds binding to melanogenesis-related proteins
  • iodobenzamides
  • melanin
  • melanin precursors
  • melanin-binding antibody
  • melanoma
  • methylene blue
  • radioimmunotherapy
  • targeted radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Melanin as a potential target for radionuclide therapy of metastatic melanoma. / Dadachova, Ekaterina; Casadevall, Arturo.

In: Future Oncology, Vol. 1, No. 4, 08.2005, p. 541-549.

Research output: Contribution to journalArticle

Dadachova, Ekaterina ; Casadevall, Arturo. / Melanin as a potential target for radionuclide therapy of metastatic melanoma. In: Future Oncology. 2005 ; Vol. 1, No. 4. pp. 541-549.
@article{cabd7891a10047238ed295ca875b6dae,
title = "Melanin as a potential target for radionuclide therapy of metastatic melanoma",
abstract = "Melanoma is diagnosed in approximately 100,000 patients worldwide and for those with metastatic disease, the 5-year survival is extremely poor at just 6{\%}, because there are no satisfactory treatments. Targeted radionuclide therapy is currently gaining momentum and has evolved into an efficient modality for the treatment of patients with malignancies such as non-Hodgkins lymphoma in whom standard antineoplastic therapies are not effective. Melanoma is named after the pigment melanin, which in turn is derived from the Greek word for black. Most melanomas are pigmented by the presence of melanin, some of which is extracellular as a result of cellular turnover. Thus, melanin presents a promising target for the drugs carrying a cytotoxic payload of radiation provided such therapies spare other melanotic tissues. There are a variety of substances that could potentially serve as delivery vehicles of radionuclides for the treatment of melanoma. These substances can be divided into melanin binders, melanin precursors and binders to melanogenesis-related proteins. The authors are optimistic that therapeutic agents targeting melanin to deliver radionuclide therapy could appear in the clinic within a decade.",
keywords = "compounds binding to melanin, compounds binding to melanogenesis-related proteins, iodobenzamides, melanin, melanin precursors, melanin-binding antibody, melanoma, methylene blue, radioimmunotherapy, targeted radiation therapy",
author = "Ekaterina Dadachova and Arturo Casadevall",
year = "2005",
month = "8",
doi = "10.2217/14796694.1.4.541",
language = "English (US)",
volume = "1",
pages = "541--549",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Melanin as a potential target for radionuclide therapy of metastatic melanoma

AU - Dadachova, Ekaterina

AU - Casadevall, Arturo

PY - 2005/8

Y1 - 2005/8

N2 - Melanoma is diagnosed in approximately 100,000 patients worldwide and for those with metastatic disease, the 5-year survival is extremely poor at just 6%, because there are no satisfactory treatments. Targeted radionuclide therapy is currently gaining momentum and has evolved into an efficient modality for the treatment of patients with malignancies such as non-Hodgkins lymphoma in whom standard antineoplastic therapies are not effective. Melanoma is named after the pigment melanin, which in turn is derived from the Greek word for black. Most melanomas are pigmented by the presence of melanin, some of which is extracellular as a result of cellular turnover. Thus, melanin presents a promising target for the drugs carrying a cytotoxic payload of radiation provided such therapies spare other melanotic tissues. There are a variety of substances that could potentially serve as delivery vehicles of radionuclides for the treatment of melanoma. These substances can be divided into melanin binders, melanin precursors and binders to melanogenesis-related proteins. The authors are optimistic that therapeutic agents targeting melanin to deliver radionuclide therapy could appear in the clinic within a decade.

AB - Melanoma is diagnosed in approximately 100,000 patients worldwide and for those with metastatic disease, the 5-year survival is extremely poor at just 6%, because there are no satisfactory treatments. Targeted radionuclide therapy is currently gaining momentum and has evolved into an efficient modality for the treatment of patients with malignancies such as non-Hodgkins lymphoma in whom standard antineoplastic therapies are not effective. Melanoma is named after the pigment melanin, which in turn is derived from the Greek word for black. Most melanomas are pigmented by the presence of melanin, some of which is extracellular as a result of cellular turnover. Thus, melanin presents a promising target for the drugs carrying a cytotoxic payload of radiation provided such therapies spare other melanotic tissues. There are a variety of substances that could potentially serve as delivery vehicles of radionuclides for the treatment of melanoma. These substances can be divided into melanin binders, melanin precursors and binders to melanogenesis-related proteins. The authors are optimistic that therapeutic agents targeting melanin to deliver radionuclide therapy could appear in the clinic within a decade.

KW - compounds binding to melanin

KW - compounds binding to melanogenesis-related proteins

KW - iodobenzamides

KW - melanin

KW - melanin precursors

KW - melanin-binding antibody

KW - melanoma

KW - methylene blue

KW - radioimmunotherapy

KW - targeted radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=33744477897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744477897&partnerID=8YFLogxK

U2 - 10.2217/14796694.1.4.541

DO - 10.2217/14796694.1.4.541

M3 - Article

VL - 1

SP - 541

EP - 549

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -